Skip to main content
SpringerLink
Log in
Book cover

Mycobacteria pp 131–160Cite as

Chemotherapy of Tuberculosis in Developed Countries

  • Chapter

Part of the book series: Chapman & Hall Medical Microbiology Series ((CHMMS))

Abstract

The chemotherapeutic era of tuberculosis began with the discovery of streptomycin (SM) in 1944 and its trial in 1945 (1,2). Soon after the introduction of isoniazid (INH) in 1952 (3), drug therapy was adopted as an important weapon in the treatment of this ancient disease. In the early stages of chemotherapy, it became apparent that drug resistance and treatment failure resulted when monotherapy with SM was used to treat active disease harboring large bacillary populations (4). The addition of a second drug to the regimen, such as para-amino-salicylic acid (PAS) or INH, prevented the emergence of drug resistance and treatment failure (5,6). Soon, the efficacy of chemotherapy was firmly established. Provided that the appropriate drug combinations were utilized against susceptible pretreatment organisms, tuberculosis could be cured within 18–24 months.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Waksman SA, Bugie E, Schatz A (1944) Isolation of antibiotic substance from soil microorganisms with special reference to streptothricin and streptomycin. Mayo Clin Proc 19:537–548.

    CAS  Google Scholar 

  2. Schatz A, Waksman SA (1944) Effect of streptomycin and other substances upon mycobacterium tuberculosis and related organisms. Proc Soc Br Med 57:244–248.

    CAS  Google Scholar 

  3. Steenken W Jr, Wolinsky E (1952) Antituberculous properties of hydrazines of isonicotinic acid (Rimifon, Marzilid). Am Rev Tuberc 65:365–375.

    PubMed  CAS  Google Scholar 

  4. British Medical Research Council (1948) Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. Br Med J 2:769–782.

    Google Scholar 

  5. British Medical Research Council (1950) Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid: a Medical Research Council investigation. Br Med J 2:1073–1085.

    Google Scholar 

  6. British Medical Research Council (1952) Treatment of pulmonary tuberculosis with isoniazid: an interim report to Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br Med J 2:735–746.

    Google Scholar 

  7. Mitchison DA (1965) Chemotherapy of tuberculosis: a bacteriologist’s viewpoint. Br Med J 1:1333–1340.

    PubMed  CAS  Google Scholar 

  8. American Thoracic Society/Centers for Disease Control (1986) Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 134:355–363.

    Google Scholar 

  9. Cowie RL, Langton ME, Escreet BC (1985) Ultrashort course chemotherapy for culture-negative pulmonary tuberculosis: a qualified success. S African Med J 68:879–880.

    CAS  Google Scholar 

  10. Grosset J (1980) Bacteriologic basis of short course chemotherapy for tuberculosis. Clin Chest Med 1:231–241.

    PubMed  CAS  Google Scholar 

  11. Fox W (1968) The John Barnwell Lecture: changing concepts in the chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 97:767–790.

    PubMed  CAS  Google Scholar 

  12. Canneti G(1965) The J. Burn’s Amberson Lecture: present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 92:687–703.

    Google Scholar 

  13. David HL (1980) Drug resistance to M. tuberculosis and other mycobacteria. Clin Chest Med 11:227–230.

    Google Scholar 

  14. Mitchison DA, Dickinson JM (1978) Bactericidal mechanisms in short course chemotherapy of tuberculosis. Bull Int Union Against Tuberc 53:270–274.

    CAS  Google Scholar 

  15. Grosset J (1978) The sterilizing value of rifampicin and pyrazinamide in experimental short course chemotherapy. Tubercle 59:287–297.

    Google Scholar 

  16. Fox W (1981) Whither short course chemotherapy? Br J Dis Chest 75:331–357.

    PubMed  CAS  Google Scholar 

  17. Mackaness GB, Smith N (1953) The bactericidal action of isoniazid, streptomycin and terramycin in extracellular and intracellular tubercle bacilli. Am Rev Respir Dis 67:322–340.

    CAS  Google Scholar 

  18. Dickinson JM, Aber VR, Mitchison DA (1977) Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am Rev Respir Dis 116:627–635.

    PubMed  CAS  Google Scholar 

  19. Clini V, Grassi C (1970) The action of new antituberculosis drugs on intracellular tubercle bacilli. Antibiot Chemother 16:20–26.

    PubMed  CAS  Google Scholar 

  20. Dickinson JM, Mitchison DA (1981) Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 123:367–371.

    PubMed  CAS  Google Scholar 

  21. Mackaness GB (1950) The intracellular activation of pyrazinamide and nicotinamide. Am Rev Tuberc 74:718–721.

    Google Scholar 

  22. Dutt AK, Stead WW (1982) Medical perspective: present chemotherapy for tuberculosis. J Infect Dis 146:698–704.

    PubMed  CAS  Google Scholar 

  23. Fox W (1979) The current status of short course chemotherapy. Tubercle 60:177–190.

    Google Scholar 

  24. Snider DE Jr, Cauthen GM, Farer LS, Kelly GD, Kilburn JO, Grood RC, Dooley SW (1991) Drug resistant tuberculosis (letter). Am Rev Respir Dis 144:732.

    PubMed  Google Scholar 

  25. Carpenter JL, Obnibene Ai, Gorby EW, Neimes RE, Koch JR, Perkins WL (1983) Antituberculosis drug resistance in South Texas. Am Rev Respir Dis 128:1055–1058.

    PubMed  CAS  Google Scholar 

  26. Chawla PK, Klapper PJ, Kamholz SL, Pollock AH, Heurich AE (1992) Drugresistant tuberculosis in an urban population including patients at risk for human immunodeficiency virus infection. Am Rev Respir Dis 146:280–284.

    PubMed  CAS  Google Scholar 

  27. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Canthen GH, Dooley SW (1993) The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328:521–526.

    PubMed  CAS  Google Scholar 

  28. Costello HD, Caras GJ, Snider DE Jr (1980) Drug resistance among previously treated tuberculosis patients: a brief report. Am Rev Respir Dis 121:313–316.

    PubMed  CAS  Google Scholar 

  29. Centers for Disease Control and Prevention (1994) Expanded tuberculosis surveillance and morbidity-United States, 1993. Morbid Mortal Wkly Rep 43 : 361–366.

    Google Scholar 

  30. Ben-Dov I, Mason GR (1987) Drug-resistant tuberculosis in a Southern California hospital: trends from 1969 to 1984. Am Rev Respir Dis 135:1307–1310.

    PubMed  CAS  Google Scholar 

  31. Barnes PF (1987) The influence of epidemiologic factors on drug resistance rates in tuberculosis. Am Rev Respir Dis 136:325–328.

    PubMed  CAS  Google Scholar 

  32. Riley LW, Arathoon E, Loverde VD (1989) The epidemiologic patterns of drugresistant Mycobacterium tuberculosis: a community-based study. Am Rev Respir Dis 139:1282–1285.

    PubMed  CAS  Google Scholar 

  33. Cantwell MF, Snider DE Jr, Cauthen GM, Onovato IM (1994) Epidemiology of tuberculosis in the United States, 1985 through 1992. J Am Med Assoc 272:532–539.

    Google Scholar 

  34. Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO (1985) Infection and disease among contacts of tuberculosis cases with drug-resistant and drugsusceptible bacilli. Am Rev Respir Dis 132:125–132.

    PubMed  Google Scholar 

  35. Steiner M, Zimmerman R, Park BH, Shinali SR, Schmidt H (1968) Primary tuberculosis in children: correlation of susceptibility patterns from M. tuberculosis isolated from children with those isolated from source case as an index of drug resistant infection in a community. Am Rev Respir Dis 8:201–209.

    Google Scholar 

  36. Nardell E, McInnis B, Thomas B, Weidhass S (1986) Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 315:1570–1575.

    PubMed  CAS  Google Scholar 

  37. Iseman MD (1993) Treatment of multidrug-resistant tuberculosis. N Engl J Med 329:784–791.

    PubMed  CAS  Google Scholar 

  38. Stead WW, Dutt AK (1982) Chemotherapy for tuberculosis today. Am Rev Respir Dis 125:94–101.

    PubMed  CAS  Google Scholar 

  39. Mitchison DA, Nunn AJ (1986) Influence of initial drug resistance in the response to short course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133:423–430.

    PubMed  CAS  Google Scholar 

  40. Mitchison DA (1992) Understanding the chemotherapy of tuberculosis: current problem. J Antimicrob Chemother 29:477–493.

    PubMed  CAS  Google Scholar 

  41. Dutt AK, Stead WW (1980) Chemotherapy of tuberculosis for the 1980s. Clin Chest Med 1:243–252.

    PubMed  CAS  Google Scholar 

  42. British Thoracic and Tuberculosis Association (1976) Short-course chemotherapy in pulmonary tuberculosis: a controlled trial. Lancet 2:1102–1104.

    Google Scholar 

  43. Dutt AK, Jones L, Stead WW (1979) Short-course chemotherapy for tuberculosis with largely twice-weekly isoniazid-rifampin. Chest 75 :441 – 447.

    PubMed  CAS  Google Scholar 

  44. Dutt AK, Moers D, Stead WW (1984) Short course chemotherapy for tuberculosis with mainly twice weekly isoniazid and rifampin: community physician’s seven years experience with mainly outpatients. Am J Med 77:233–242.

    PubMed  CAS  Google Scholar 

  45. Dutt AK, Moers D, Stead WW (1980) Results of short course chemotherapy for tuberculosis in patients with complicating medical disorders. Chest 78:514 (abstract).

    Google Scholar 

  46. Dutt AK, Moers D. Stead WW (1986) Short course chemotherapy for extrapulmonary tuberculosis. Ann Intern Med 104:7–12.

    PubMed  CAS  Google Scholar 

  47. Abernathy RS, Dutt AK, Stead WW, Moers DJ (1983) Short course chemotherapy for tuberculosis in children. Pediatrics 12:801–806.

    Google Scholar 

  48. Snider DE Jr, Zierski M, Graczyk J, et al. (1986) Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade. Eur J Respir Dis 68:12–18.

    PubMed  Google Scholar 

  49. Manalo F, Tan F, Sbarbaro JA, Iseman MD (1990) Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Am Rev Respir Dis 142:1301–1305.

    PubMed  CAS  Google Scholar 

  50. Steele MA, Des Prez RM (1988) The role of pyrazinamide in tuberculosis chemotherapy. Chest 94:845–850.

    PubMed  CAS  Google Scholar 

  51. Girling DJ (1989) The chemotherapy of tuberculosis. Biol Mycobact 3:285–294.

    Google Scholar 

  52. Centers for Disease Control (1993) Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. Morbid Mortal Wkly Rep 42(RR-7):1–8.

    Google Scholar 

  53. Goble M (1986) Drug resistant tuberculosis. Semin Respir Infect 1:220–229.

    PubMed  CAS  Google Scholar 

  54. Iseman MD, Madsen LA (1989) Drug-resistant tuberculosis. Clin Chest Med 10:341–353.

    PubMed  CAS  Google Scholar 

  55. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CRIV, (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 328:527–532.

    PubMed  CAS  Google Scholar 

  56. Imamura N, Vanderkolk J, Heifets L (1994) Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob. Agents Chemotherap. 38(5):1161–1164.

    Google Scholar 

  57. Iseman MD, Madsen L, Goble M, Pomerantz M (1990) Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis 141:623–625.

    PubMed  CAS  Google Scholar 

  58. Stead WW, To T, Harrison RW, Abraham JH III (1987) Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 107:843–845.

    PubMed  CAS  Google Scholar 

  59. International Union Against Tuberculosis Committee on Prophylaxis (1982) Efficacy of various duration of isoniazid preventive therapy for tuberculosis: five year followup in the IVAT trial. Bull WHO 60:555–564.

    Google Scholar 

  60. Koplan JP, Farer LS (1980) Choice of preventive treatment for isoniazid-resistant tuberculosis infection. J Am Med Assoc 244:2736–2740.

    CAS  Google Scholar 

  61. Centers for Disease Control (1992) Management of persons exposed to multidrugresistant tuberculosis. Morbid Mortal Wkly Rep 41(RR-11):61–74.

    Google Scholar 

  62. Centers for Disease Control. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the advisory council for the elimination of tuberculosis. MMWR 1996;45(RR-4):1–18.

    Google Scholar 

  63. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC (1992) Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 324:289–294.

    Google Scholar 

  64. Jones BE, Otaya M, Antoniskis D, Sian S, Wang F, Mercado A, Davidson PT, Barnes PF (1994) A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 150:1499— 1502.

    PubMed  CAS  Google Scholar 

  65. Centers for Disease Control (1991) Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons: Florida and New York 1988–1991. Morbid Mortal Wkly Rep 40(34):585–591.

    Google Scholar 

  66. Edlin BR, Tokars JI, Grieco MH, Crawford JT, William J, Sordillo EM, Ong KR, Kilburn J, Dooley SW, Castro KG, Jarvis WR, Holmberg SD (1992) An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 326:1514–1521.

    PubMed  CAS  Google Scholar 

  67. Alwood K, Kevuly J, Moore-Rice K, Stanton DL, Chaulk CD, Chaisson RE (1994) Effectiveness of supervised intermittent therapy for tuberculosis in HIV infection. AIDS 8:1103–1108.

    PubMed  CAS  Google Scholar 

  68. Fischl MA, Daikos GL, Uttamchandani RD, Poblete RB, Moreno JN, Reyes RR, Boota AM, Thompson LM, Cleary TJ, Oldham SA (1992) Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple drug resistant bacilli. Ann Intern Med 117:184–190.

    PubMed  CAS  Google Scholar 

  69. A comparative study of daily and twice-weekly continuation regimens of tuberculosis chemotherapy, including a comparison of two durations of sanatorium treatment. I. First report: the results at 12 months. Bull World Health Organ 1971:45(5):573–593.

    Google Scholar 

  70. Starke JR (1990) Multidrug therapy for tuberculosis in children. Pediatr Infect Dis J 9:785–793.

    PubMed  CAS  Google Scholar 

  71. Committee on Infectious Diseases (1991) Report of the Committee on Infectious Diseases, 22nd Ed., Elk Grove, IL: American Academy of Pediatrics.

    Google Scholar 

  72. Anonymous: Smear negative pulmonary tuberculosis. Tubercle 1980;61:113–115.

    Google Scholar 

  73. Narain R, Nair SS, Naganna K (1968) Problem of defining a case of pulmonary tuberculosis in prevalence survey. Bull WHO 39:701–729.

    PubMed  CAS  Google Scholar 

  74. Dutt AK, Stead WW (1994) Smear-negative pulmonary tuberculosis. Semin Respir Infect 9(2):113–119.

    PubMed  CAS  Google Scholar 

  75. Singapore Tuberculosis Service/British Medical Research Council (1986) Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 133:779–783.

    Google Scholar 

  76. Hong Kong Chest Service/Tuberculosis Research Center Madras/British Medical Research Council (1989) A controlled trial of 3-month, 4-month and 6-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: results at 5 years. Am Rev Respir Dis 139:871–876.

    Google Scholar 

  77. American Thoracic Society/Centers for Disease Control (1994) Recommendations for the treatment and preventive treatment of tuberculosis. Am J Respir Crit Car Med 151:1359–1374.

    Google Scholar 

  78. Dutt AK, Moers D, Stead WW (1990) Smear-negative culture-positive pulmonary tuberculosis: six months chemotherapy with isoniazid and rifampin. Am Rev Respir Dis 144:1232–1235.

    Google Scholar 

  79. Dutt AK, Moers D, Stead WW (1992) Tuberculous pleural effusion: six month therapy with isoniazid and rifampin. Am Rev Respir Dis 145:1429–1432.

    PubMed  CAS  Google Scholar 

  80. Ormerod LP, McCarthy OR, Rudd RM, Horsfield N, (1995) Short course chemotherapy for tuberculous pleural effusion and culture-negative pulmonary tuberculosis. Tuber Lung Dis 76:25–27.

    PubMed  CAS  Google Scholar 

  81. Dutt AK, Moers D, Stead WW (1989) Smear- and culture-negative pulmonary tuberculosis: four months short course chemotherapy. Am Rev Respir Dis 139:867–870.

    PubMed  CAS  Google Scholar 

  82. Snider DE Jr, Layde RN, Johnson MW, Lyle MA (1980) Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 122:65–79.

    PubMed  Google Scholar 

  83. Snider DE Jr, Powell KE (1984) Should women taking antituberculosis drugs breast feed? Arch Intern Med 144:589–590.

    PubMed  Google Scholar 

  84. Hamadeh MA, Glassroth J (1992) Tuberculosis and pregnancy. Chest 101:1114–1120.

    PubMed  CAS  Google Scholar 

  85. Cross FS, Long MW, Banner AS, Snider DE, Jr (1980) Rifampin-isoniazid therapy of alcoholic and non-alcoholic tuberculosis patients in a U.S. Public Health Service Cooperative Therapy trial. Am Rev Respir Dis 122:349–353.

    PubMed  CAS  Google Scholar 

  86. Andrew OT, Schoenfeld PY, Hopewell PC, Humphrey’s MH (1980) Tuberculosis in patients with end-stage renal disease. Am J Med 68:59–65.

    PubMed  CAS  Google Scholar 

  87. Dautzenberg B, Grosset J, Fechner J, Luccianni, Debra P, Hersons S, Truffot C, Sors C (1984) The management of thirty immunocompromised patients with tuberculosis. Am Rev Respir Dis 129:494–496.

    PubMed  CAS  Google Scholar 

  88. Davidson PT, Le HQ: Drug treatment of tuberculosis-1992. Drugs 43:651–673.

    PubMed  CAS  Google Scholar 

  89. Masud T, Kemp E (1988) Corticosteroids in treatment of disseminated tuberculosis in patients with HIV infection. Br Med J 296:464–465.

    CAS  Google Scholar 

  90. Strang JIG, Kakaza MMS, Gibson DG, Allen BW, Mitchison DA, Evans DJ, Girling DJ, Nunn AJ, Fox, W (1988) Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet 2:759–764.

    PubMed  CAS  Google Scholar 

  91. Brudney K, Dobkin J (1991) Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness and the decline of tuberculosis program. Am Rev Respir Dis 144:745–749.

    PubMed  CAS  Google Scholar 

  92. Mahmoudi A, Iseman MD (1993) Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. J Am Med Assoc 270:65–68.

    CAS  Google Scholar 

  93. Brudney K, Dobkin J (1991) A tale of two cities: tuberculosis in Nicaragua and New York City. Semin Respir Infect 6:261–272.

    PubMed  CAS  Google Scholar 

  94. Weis SE, Slocum PC, Blais FX, King B, Matney GB, Gomez E, Foresman BH (1994) The effect of directly observed therapy on the rate of drug resistance and relapse in tuberculosis. N Engl J Med 330:1179–1184.

    PubMed  CAS  Google Scholar 

  95. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA, (1990) A 62-dose, sixmonth therapy for pulmonary and extrapulmonary tuberculosis: a twice weekly, directly observed and cost-effective regimen. Ann Intern Med 112:407–415.

    PubMed  CAS  Google Scholar 

  96. Iseman MD, Cohn DL, Sbarbaro JA (1993) Directly observed treatment of tuberculosis: we can’t afford not to try it. N Engl J Med 328:576–578.

    PubMed  CAS  Google Scholar 

  97. Moulding T, Dutt AK, Reichman LB (1998) Fixed dose combinations of antituberculosis medications to prevent drug resistance. Ann Intern Med 122:951— 954.

    Google Scholar 

  98. Van-den-Brande P, Van-Steenbergen W, Vervoort G, Demedts M (1995) Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis Am J Respir Crit Care Med 152, 1705–1708.

    CAS  Google Scholar 

  99. Byrd RB, Horn BR, Soloman DA, Griggs GA, (1979) Toxic effects of isoniazid in tuberculosis chemoprophylaxis: role of biochemical monitoring in 1000 patients. J Am Med Assoc 241:1239–1241.

    CAS  Google Scholar 

  100. Bailey WC, Taylor SC, Dascomb WH, Greenberg HB, Ziskind MM (1973) Disturbed hepatic function during isoniazid chemoprophylaxis. Am Rev Respir Dis 107:523— 529.

    PubMed  CAS  Google Scholar 

  101. Dutt AK, Moers D, Stead WW (1983) Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis. Am Rev Respir Dis 128:419–424.

    PubMed  CAS  Google Scholar 

  102. Girling DJ (1978) The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 59:13–32.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Asim K. Dutt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jay B. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Chicago College of Medicine, University of Illinois, Chicago, Illinois, USA

    Pattisapu R. J. Gangadharam Ph.D. (Professor of Medicine, Microbiology, and Pathology, Director of Mycobacteriology Research) (Professor of Medicine, Microbiology, and Pathology, Director of Mycobacteriology Research)

  2. Public Health Laboratory Service, University Hospital of Wales, UK

    P. Anthony Jenkins Ph.D. (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Dutt, A.K., Mehta, J.B. (1998). Chemotherapy of Tuberculosis in Developed Countries. In: Gangadharam, P.R.J., Jenkins, P.A. (eds) Mycobacteria. Chapman & Hall Medical Microbiology Series. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-7511-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-7511-5_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4615-7513-9

  • Online ISBN: 978-1-4615-7511-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation